Results 121 to 130 of about 114,789,047 (289)
Targeting KRAS for cancer therapy
British Journal of Pharmacology, EarlyView.In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia +4 more
wiley +1 more source
Adverse Effects Linked to Counterfeit or Mishandled Botulinum Toxin Injections [PDF]
Distributed via the CDC Health Alert NetworkApril 23 2024, 11:00 AM ETCDCHAN-00507The Centers for Disease Control and Prevention (CDC) is issuing this Health Alert Network (HAN) Health Advisory to alert clinicians about risks of counterfeit or mishandled
core
Botulinum toxin type A iontophoresis for post-burn hypertrophic scars: a randomised controlled trial
Introduction Hypertrophic scars (HSs) are caused by excessive collagen synthesis due to fibroblast proliferation. Botulinum toxin type A (BoNT-A) slows fibroblast proliferation and collagen deposition, thereby improving HSs.
Hayam M. Alnawagy +4 more
core +1 more source
EPHX2 Loss Promotes CRC Migration via EET‐Dependent Chemokine Elevation and Mitochondrial Defect
Cancer Science, EarlyView.Loss of EPHX2 promotes EET accumulation, which in turn enhances CXCL and ROS production, thereby promoting the migratory and invasive abilities of CRC cells. ABSTRACT Epoxide hydrolase 2 (EPHX2) is a key enzyme in fatty acid metabolism that metabolizes epoxyeicosatrienoic acids (EETs), lipid mediators involved in inflammation, angiogenesis, and ...
Jianjun Zhu +10 more
wiley +1 more source
A Case Report of Herpes Zoster After Botulinum Toxin Injections [PDF]
Shadi Zari Department of Dermatology, College of Medicine, University of Jeddah, Jeddah, Saudi ArabiaCorrespondence: Shadi Zari, Department of Dermatology, College of Medicine, University of Jeddah, Saudi Arabia, Email Shadizarimd@gmail.comAbstract: This
Zari S
core
, 2006 Most of the initial reports on botulinum toxin in tension-type headache (TTH) and in migraine were positive. Unfortunately, these results were not reproduced in well-designed, randomized controlled trials.
Schulte-Mattler, W. J. +1 more
core +1 more source
[Botulinum toxin type B in the management of dystonia non-responsive to botulinum toxin type A].
Arquivos de neuro-psiquiatria, 2004 Botulinum toxin (BTX) injection is the first choice treatment for focal dystonias. However 10% or more of patients who receive repetitive injections of BTX type A (BTX-A) lose response (secondary non-responders). One of the strategies to manage such patients is to treat them with another serotype.
openaire +2 more sources
Journal of Cutaneous Pathology, EarlyView.ABSTRACT Background Hailey‐Hailey disease (HHD) is a rare autosomal dominant blistering disorder caused by mutations in the ATP2C1 gene, which impair keratinocyte adhesion through disrupted calcium signaling. While traditionally considered a structural defect, recent studies suggest that Th2‐mediated inflammation may exacerbate disease pathology ...
Simonetta I. Gaumond +6 more
wiley +1 more source
Exploring the psychosocial impact of undergoing botulinum toxin treatment
, 2014 In 2012, the American Society for Plastic Surgeons reported that 13 million minimally invasive treatments, such as botulinum toxin injections and dermal fillers, were performed in the US.
Paraskeva, Nicole
core +1 more source